213 related articles for article (PubMed ID: 36709426)
21. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
[TBL] [Abstract][Full Text] [Related]
22. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
23. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
Cao W; Yang Q; Yuan Z; Li H; Wang W; Xiao X; Wang Z; Liang L; Zhou P; Liu J; Hu X; Zhang B
Biochem Biophys Res Commun; 2020 Apr; 524(3):549-554. PubMed ID: 32014255
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
26. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y; Lin FT; Lin WC
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
[TBL] [Abstract][Full Text] [Related]
27.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
Ther Adv Respir Dis; 2020; 14():1753466620918192. PubMed ID: 32401173
[TBL] [Abstract][Full Text] [Related]
28. Impact of biomarkers on non-small cell lung cancer treatment.
Toschi L; Cappuzzo F
Target Oncol; 2010 Mar; 5(1):5-17. PubMed ID: 20443070
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Li Y; Köpper F; Dobbelstein M
Cancer Lett; 2018 Aug; 428():45-54. PubMed ID: 29704518
[TBL] [Abstract][Full Text] [Related]
30. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
31. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
32. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
Ikeda R; Vermeulen LC; Lau E; Jiang Z; Sachidanandam K; Yamada K; Kolesar JM
Int J Oncol; 2011 Feb; 38(2):513-9. PubMed ID: 21152861
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
35. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
[TBL] [Abstract][Full Text] [Related]
38. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Gao Z; Han B; Shen J; Gu A; Zhong H
Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
[TBL] [Abstract][Full Text] [Related]
39. Chemoresistance in non-small cell lung cancer.
Sève P; Dumontet C
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):73-88. PubMed ID: 15720263
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S; Goa KL
Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
